Mounjaro Sales Slowdown Tied to Supply Issues

Key Findings on Sales Deceleration

Morgan Stanley attributes the recent slowdown in Mounjaro sales to significant supply constraints rather than a decline in consumer demand. Retailers consistently report limited product availability despite strong underlying customer interest.

Supply Chain and Import Analysis

Weak U.S. GLP-1 imports during December and January likely restricted sales figures. However, a sharp rebound in February imports suggests a potential near-term recovery, which will be closely watched in IQVIA data for confirmation.

Market and Pricing Landscape

The competitive landscape shows competitor Semaglutide facing structural challenges as patients switch to Mounjaro. Pricing for Mounjaro remains broadly stable, with only early signs of selective discounts and no evidence of widespread price cuts from manufacturers like Novo Nordisk.

Outlook

The key takeaway is that Mounjaro's sales momentum is supply-dependent. An improvement in import trends could de-risk near-term sales forecasts for related retailers, though market confirmation through official data is still pending.

FAQ

Q: Why did Mounjaro sales slow down?
A: According to Morgan Stanley, the slowdown was primarily caused by supply constraints and limited product availability, not by weakening demand.

Q: Is the price of Mounjaro decreasing?
A: Pricing is generally stable. While there are early signs of selective discounts, there is no evidence of broad, portfolio-wide price cuts.

Source: Investing.com